ArticleBMC public health2024
Trends in parkinson's disease mortality in China from 2004 to 2021: a joinpoint analysis.
Article in BMC public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Prevalence and spatial distribution characteristics of human brucellosis in Ningxia from 2010 to 2024.PLoS neglected tropical diseases · 2026Article
- Astrocytes in Parkinson's Disease: From Guardians to Accomplices.Clinical interventions in aging · 2026Review
- Real-world analysis and future trends of parkinson's disease burden and all-cause mortality in Shanghai Pudong: a population-based study of 3.17 million people.BMC public health · 2025Article
- Asperuloside: an emerging therapeutic candidate for Parkinson's disease through molecular mechanistic insights.Inflammopharmacology · 2025Review
- Mortality and causes of death in patients with Parkinson's disease in Taiwan.Journal of Parkinson's disease · 2025Article
- Chronic obstructive pulmonary disease burden attributable to tobacco and the trend change from 1990 to 2021 in China.Tobacco induced diseases · 2025Article
- Burden of neurologic diseases in BRICS countries (1990 to 2021): an analysis of 2021 Global Burden of Disease Study.Frontiers in neurology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThis study aimed to analyze the trends of Parkinson's disease (PD) mortality rates among Chinese residents from 2004 to 2021, provide evidence for the formulation of PD prevention and control strategies to improve the quality of life among PD residents.
methodsDemographic and sociological data such as gender, urban or rural residency and age were obtained from the National Cause of Death Surveillance Dataset from 2004 to 2021. We then analyzed the trends of PD mortality rates by Joinpoint regression.
resultsThe PD mortality and standardized mortality rates in China showed an overall increasing trend during 2004-2021 (average annual percentage change [AAPC] = 7.14%, AAPC
conclusionsThe mortality rate of PD among Chinese residents increased from 2004 to 2021. Male sex, urban residence and age > 85 years were risk factors for PD-related death and should be the primary focus for PD prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.